Galapagos - New CAR-T data shared at ASH conference
*Updated CAR-T data from GLPG5101 and 5201, incl. from Ph2 part of ATALANTA-1, provide further validation for GLPG's point-of-care manufacturing method. Efficacy data, although encouraging, are still immature, from a limited number of patients only, and from a variety of cancer types. Hence, we consider it too early to draw conclusions on the therapeutic potential of these assets.*The road to market remains long with, especially the NHL space, being relatively crowded with several anti-CD19 CAR-Ts already available and moving up the treatment cascade.*We stick to our HOLD rating considering the lack of significant pipeline inflection points in the near-to mid-term.Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.